Zydus Lifesciences Partners Apollo Hospitals for India's Multi-Cancer Detection Test Expansion

Zydus Lifesciences Limited has entered into a Memorandum of Understanding (MoU) with Apollo Hospitals to significantly expand access to the Shield™ Multi-Cancer Detection (MCD) test across India. This collaboration builds on Zydus's exclusive agreement with Guardant Health, Inc., which developed the methylation-based blood test. The partnership aims to enhance early cancer detection for individuals aged 45 or older who are at typical average risk for cancer, leveraging Apollo Hospitals' network.

Key highlights

• Zydus Lifesciences signed an MoU with Apollo Hospitals to offer the Shield™ Multi-Cancer Detection (MCD) test in India.
• This expands upon Zydus's existing exclusive agreement with Guardant Health, Inc., the developer of the Shield™ MCD test.
• The test screens for 10 common cancer types, including bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian, and pancreas cancer.
• It is designed for individuals aged 45 or older and at typical average risk, requiring only a blood draw.
• The Shield™ MCD test has received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA), acknowledging its potential for more effective cancer screening than existing options.

Strategic rationale

Zydus Lifesciences is expanding access to precision diagnostics as part of its commitment to unlocking new possibilities in patient care, aligning with its position as an oncology company. The collaboration with Apollo Hospitals and Guardant Health is intended to complement existing screening pathways and encourage timely screening and proactive healthcare. This initiative responds to the challenge of cancer, which accounts for nearly nine percent of non-communicable disease-related deaths in India, with screening rates remaining low nationally. Apollo Hospitals emphasized that effective healthcare involves preventing disease and detecting it at its earliest, most treatable stages.

Focus areas

The partnership is focused on the widespread availability of the methylation-based Shield™ Multi-Cancer Detection (MCD) test. This blood test is engineered for the detection of multiple cancer types, specifically targeting bladder, colorectal, breast, prostate, oesophageal, gastric, liver, lung, ovarian, and pancreas cancer. The test aims to identify cancer-associated signals through a single blood draw.

Why it matters

This collaboration marks an important step in advancing accessible, patient-friendly cancer screening solutions for individuals in India. By making an innovative multi-cancer detection test available through a prominent hospital network, Zydus aims to empower individuals with the opportunity for earlier diagnoses. Earlier detection has the potential to significantly improve treatment success rates, contributing to a reduction in cancer-related mortality, which remains a substantial public health challenge in the country. This initiative represents an effort to transform cancer outcomes through proactive healthcare.

What to watch

Future disclosures may detail the phased rollout strategy for the Shield™ MCD test across Apollo Hospitals' facilities and any associated public awareness campaigns. Monitoring the adoption rate of this screening solution and its geographic expansion could provide further insight into its impact.